中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

59 records (took 0.044 seconds)

    폴리글리세릴계 유화제를 포함하는 나노에멀젼 조성물
    52.
    发明公开
    폴리글리세릴계 유화제를 포함하는 나노에멀젼 조성물 审中-实审
    包含聚甘油基乳化剂的纳米乳液组合物

    公开(公告)号：KR1020170124320A

    公开(公告)日：2017-11-10

    申请号：KR1020160054078

    申请日：2016-05-02

    Applicant: (주)아모레퍼시픽

    Inventor： 김수일 ,  신홍주 ,  정연수 ,  이창근 ,  김정환 ,  박영호

    IPC: A61K8/39 ,  A61K8/68 ,  A61K8/34 ,  A61K8/06 ,  A61K8/04 ,  A61Q19/00

    CPC classification number: A61K8/04 ,  A61K8/06 ,  A61K8/34 ,  A61K8/39 ,  A61K8/68 ,  A61Q19/00

    Abstract: 본발명은폴리글리세릴계유화제조합을통해보다안정도가증진된나노에멀젼조성물및 이의제조방법에관한것이다. 본발명에의한나노에멀젼조성물은입자의입도와분포면에서종전의나노에멀젼에비해월등하게우수한특성을지니고, 제조방법또한기존방법보다저렴하고간편하며, PEG계화합물사용을제한하여안전성면에서도우수하므로, 본발명에의한나노에멀젼조성물및 이의제조방법은다양한분야에서널리활용될수 있을것이다.

    Abstract translation: 本发明涉及通过组合聚甘油基润滑剂及其制备方法而具有增强的稳定性的纳米乳液组合物。 相比于传统的纳米乳剂月在颗粒尺寸和颗粒，生产方法也便宜且比现有方法更简单，的分布方面，通过限制使用安全的在基于PEG的化合物的术语根据本发明的纳米乳剂组合物具有优异的性能如这样 根据本发明的纳米乳液组合物及其制备方法可广泛用于各种领域。

    콩 추출물을 함유하는 혈액 순환 개선 및 혈관 건강 증진용 조성물
    55.
    发明公开
    콩 추출물을 함유하는 혈액 순환 개선 및 혈관 건강 증진용 조성물 审中-实审
    包含用于改善血液循环和血管健康的豆提取物的组合物

    公开(公告)号：KR1020100127728A

    公开(公告)日：2010-12-06

    申请号：KR1020100049181

    申请日：2010-05-26

    Applicant: (주)아모레퍼시픽

    Inventor： 신현정 ,  김진관 ,  김채욱 ,  주경미 ,  정연수 ,  임경민 ,  서대방 ,  주영협 ,  이상준 ,  박영호

    IPC: A61K36/48 ,  A23L1/30 ,  A23L2/52

    CPC classification number: A61K36/48 ,  A23L2/52 ,  A23L33/105 ,  A61K2236/333 ,  A23V2200/30

    Abstract: PURPOSE: A composition containing soybean extract isolated with low alcohol is provided to improve blood circulation and to treat obesity, diabetes, and hyperlipidemia. CONSTITUTION: A composition for improving blood circulation contains soybean extract isolating with 1-7% of C1-5 alcohol or fraction. The C1-5 alcohol is methanol, ethanol, isopropylalcohol, n-propylalcohol, n-butanol or isobutanol. The soybean extract or fraction contains adenosine. The fraction is an ethylacetate or butanol fraction. The composition suppresses thrombosis or cholesterol generation.

    Abstract translation: 目的：提供含有用低分子量分离的大豆提取物的组合物，以改善血液循环和治疗肥胖症，糖尿病和高脂血症。 构成：用于改善血液循环的组合物含有用1-7％的C1-5醇或级分分离的大豆提取物。 C 1-5醇是甲醇，乙醇，异丙醇，正丙醇，正丁醇或异丁醇。 大豆提取物或级分含有腺苷。 馏分是乙酸乙酯或丁醇馏分。 该组合物抑制血栓形成或胆固醇的产生。

    바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
    57.
    发明公开
    바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물 有权
    新型化合物，异构体或其药学上可接受的盐作为VANULLOID受体拮抗剂和含有其的药物组合物

    公开(公告)号：KR1020100053470A

    公开(公告)日：2010-05-20

    申请号：KR1020090108632

    申请日：2009-11-11

    Applicant: (주)아모레퍼시픽

    Inventor： 김선영 ,  김연준 ,  남미희 ,  이기화 ,  신송석 ,  우병영 ,  임경민 ,  정연수 ,  모주현 ,  최진규 ,  고현주 ,  이정오 ,  김혁 ,  윤정훈

    IPC: C07D323/04 ,  A61K31/357

    Abstract: PURPOSE: A novel compound which functions as a vanilloid receptor 1(VR1) antagonist is provided to prevent or treat disease related to hair growth, rhinitis, and pancreatitis. CONSTITUTION: A vanilloid receptor antagonist compound is denoted by chemical formula I. A pharmaceutical composition contains the compound, isomer, or pharmaceutically acceptable salt thereof. The composition is used for preventing or treating arthritis disease, neuropathy, HIV related neuropathy, nerve injury, neurodegeneration, cerebral apoplexy, urinary incontinence, cough, neuropathy/allergy/inflammation skin disease, atopic dermatitis, psoriasis, pruritus, the prurigo, acouesthesia, aliasing, bregma anaphylaxis, effluvium, or alopecia.

    Abstract translation: 目的：提供作为香草素受体1（VR1）拮抗剂起作用的新型化合物，以预防或治疗与毛发生长，鼻炎和胰腺炎有关的疾病。 构成：香草素受体拮抗剂化合物由化学式I表示。药物组合物含有化合物，异构体或其药学上可接受的盐。 该组合物用于预防或治疗关节炎疾病，神经病，HIV相关神经病，神经损伤，神经变性，脑中风，尿失禁，咳嗽，神经病变/过敏/炎症皮肤病，特应性皮炎，牛皮癣，瘙痒，瘙痒症，麻醉， 混叠，原发性过敏性反应，流出或脱发。

    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물
    58.
    发明公开
    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 有权
    新化合物，其异构体，或其药学上可接受的盐作为VANILLOID受体拮抗剂; 和含有它们的药物组合物

    公开(公告)号：KR1020080007329A

    公开(公告)日：2008-01-18

    申请号：KR1020077024002

    申请日：2006-03-15

    Applicant: (주)아모레퍼시픽

    Inventor： 김희두 ,  서영거 ,  박형근 ,  오우택 ,  박설린 ,  김주현 ,  장미정 ,  박영호 ,  신송석 ,  김선영 ,  김진관 ,  정연수 ,  이기화 ,  최진규 ,  임경민 ,  고현주 ,  모주현 ,  김성일 ,  우병영

    IPC: C07C275/24 ,  C07C275/18 ,  A61K31/17

    CPC classification number: C07C275/24 ,  C07C311/08 ,  C07C311/11 ,  C07C323/62 ,  C07D211/46 ,  C07D295/088 ,  C07D295/155 ,  C07D309/12 ,  C07F7/0818

    Abstract: A compound as a vanilloid receptor antagonist is provided to obtain a pharmaceutical composition effective for preventing or treating pain, migraine, arthralgia, nerve injury, skin diseases, overactive bladder, irritable bowel syndrome, or the like. A compound as a vanilloid receptor antagonist, an isomer or a pharmaceutically acceptable salt thereof is represented by the following formula I. In formula I, X is NHCH2, CR11=CR12, NH, CHR11CHR12 or C=C, wherein each of R11 and R12 represents H, halogen, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl or phenyl; R1 is a C2-C5 alkenyl or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl(C1-C3)alkyl, wherein is each phenyl group is non-substituted or substituted with at least one substituent; R3 is H, C1-C5 alkyl, C1-C5 alkoxy or halo(C1-C5)alkyl; each of R4, R5 R6, R7 and R8 independently represents H, carboxyl, C1-C5 alkyl, nitro, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkynyl, halo(C1-C5)alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, hydroxy, C2-C5 alkenyloxy, C1-C5 alkoxy(C1-C5)alkoxy, C1-C5 alkoxy(C1-C5)alkoxy(C1-C5)alkyl, C1-C3 alkylpiperazinyl, piperazinyl(C1-C5)alkoxy, piperidinyl(C1-C5)alkoxy, C1-C5 alkoxy (C1-C5)alkylamino, C1-C7 alkylamino, morpholinyl, morpholinyl(C1-C5)alkyloxy, tetrahydropyranyloxy, phenyl or halogen, wherein each phenyl group is non-substituted or substituted with at least one substituent; each of R9 and R10 independently represents H, -SO2R13, -SOR13, C1-C5 alkyl, C1-C5 alkoxy, halo (C1-C5)alkyl, C2-C5 alkenyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl (C1-C3)alkyl, wherein each phenyl group is non-substituted or substituted with at least one substituent, and R13 is H, amino, C1-C5 alkyl, C2-C5 alkenyl, C1-C5 alkoxy, halo(C1-C5)alkyl, trifluoromethyl, phenyl or phenyl(C1-C3)alkyl.

    Abstract translation: 提供作为香草素受体拮抗剂的化合物以获得有效预防或治疗疼痛，偏头痛，关节痛，神经损伤，皮肤疾病，膀胱过度活动症，肠易激综合征等的药物组合物。 作为香草酸受体拮抗剂的化合物，其异构体或其药学上可接受的盐由下式I表示。在式I中，X为NHCH 2，CR 11 = CR 12，NH，CHR 11 CHR 12或C = C，其中R 11和R 12 表示H，卤素，C 1 -C 5烷基，C 1 -C 5烷氧基，卤代（C 1 -C 5）烷基或苯基; R1是C2-C5烯基或C2-C5炔基; R2是H，卤素，硝基，氰基，C1-C5烷基，C1-C5烷氧基，卤代（C1-C5）烷基，C2-C5烯基或C2-C5炔基; R2是H，卤素，硝基，氰基，C1-C5烷基，C1-C5烷氧基，卤代（C1-C5）烷基，C2-C5烯基，C2-C5炔基，羧基，C1-C5烷氧羰基，C1-C5烷硫基， 苯基或苯基（C1-C3）烷基，其中每个苯基是未取代的或被至少一个取代基取代; R3是H，C1-C5烷基，C1-C5烷氧基或卤代（C1-C5）烷基; R 4，R 5，R 6，R 7和R 8各自独立地表示H，羧基，C 1 -C 5烷基，硝基，C 2 -C 5烯基，C 1 -C 5烷氧基，C 2 -C 5炔基，卤代（C 1 -C 5）烷基，C 1 -C 5烷硫基 ，C1-C5烷基磺酰基，C1-C5烷基羰基，C1-C5烷氧基羰基，羟基，C2-C5链烯氧基，C1-C5烷氧基（C1-C5）烷氧基，C1-C5烷氧基（C1-C5）烷氧基（C1-C5）烷基 （C1-C5）烷氧基，C1-C5烷氧基（C1-C5）烷基氨基，C1-C7烷基氨基，吗啉基，吗啉基（C1-C5）烷氧基，四氢吡喃基氧基， 苯基或卤素，其中每个苯基未被取代或被至少一个取代基取代; R 9和R 10各自独立地表示H，-SO 2 R 13，-SOR 13，C 1 -C 5烷基，C 1 -C 5烷氧基，卤代（C 1 -C 5）烷基，C 2 -C 5烯基，C 1 -C 5烷氧基羰基，C 1 -C 5烷硫基，苯基或 苯基（C1-C3）烷基，其中每个苯基未被取代或被至少一个取代基取代，R 13是H，氨基，C 1 -C 5烷基，C 2 -C 5烯基，C 1 -C 5烷氧基，卤代（C1- C5）烷基，三氟甲基，苯基或苯基（C1-C3）烷基。

    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물
    59.
    发明公开
    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 有权
    新化合物，其异构体，或其药学上可接受的盐作为VANILLOID受体拮抗剂; 和含有它们的药物组合物

    公开(公告)号：KR1020070114821A

    公开(公告)日：2007-12-04

    申请号：KR1020077024004

    申请日：2006-03-17

    Applicant: (주)아모레퍼시픽

    Inventor： 서영거 ,  김희두 ,  박형근 ,  오우택 ,  이용실 ,  박설린 ,  유정현 ,  박영호 ,  신송석 ,  김선영 ,  김진관 ,  정연수 ,  이기화 ,  최진규 ,  임경민 ,  고현주 ,  모주현 ,  김성일 ,  배준호

    IPC: C07C275/24 ,  C07C275/18 ,  A61K31/17

    CPC classification number: C07C275/24 ,  C07C311/08 ,  C07C311/11 ,  C07C323/62 ,  C07D211/46 ,  C07D295/088 ,  C07D295/155 ,  C07D309/12 ,  C07F7/0818

    Abstract: A compound as a vanilloid receptor antagonist is provided to obtain a high activity in preventing or treating pain, migraine, arthralgia, neuralgia, neural diseases, neural injury, skin diseases, irritable bowel syndrome, inflammatory diseases, cardiac diseases, etc. A compound as a vanilloid receptor antagonist is a compound represented by the following formula Ia or an isomer and/or pharmaceutically acceptable salt thereof. In formula Ia, X is CR11=CR12 or C=C, wherein each of R11 and R12 independently represents H, a halogen atom, C1-C5 alkyl or phenyl; each of R1 and R2 independently represents H, carboxyl, C1-C5 alkyl, halogen, nitro, C1-C5 alkoxy, halo(C1-C5)alkyl, C1-C5 alkylcarbonyl, C1-C5 alkylcarbonylamino, C1-C5 alkylsulfonylamino, phenylsulfonylamino, C1-C5 alkylthio, C1-C5 alkylsulfonyl or C1-C5 alkoxycarbonyl; R3 is H, C1-C5 alkyl, C1-C5 alkoxy or halo(C1-C5)alkyl; each of R4, R5, R6, R7 and R8 independently represents H, carboxyl, C1-C5 alkyl, nitro, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkynyl, halo(C1-C5)alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, phenyl or halogen, wherein the phenyl is non-substituted or substituted with at least one substituent selected from carboxyl, C1-C5 alkyl, halogen, nitro, C2-C5 alkenyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C1-C5 alkylcarbonyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl and C1-C5 alkoxycarbonyl; R9 is C1-C5 alkylsulfonyl or C2-C5 alkenylsulfonyl; and R10 is H, with the proviso that when R3 is not H, R11 and R13 cannot represent H at the same time.

    Abstract translation: 提供了一种作为香草素受体拮抗剂的化合物，用于预防或治疗疼痛，偏头痛，关节痛，神经痛，神经疾病，神经损伤，皮肤病，肠易激综合征，炎性疾病，心脏病等中的高活性。 香草酸受体拮抗剂是由下式Ia表示的化合物或其异构体和/或其药学上可接受的盐。 在式Ia中，X是CR 11 = CR 12或C = C，其中R 11和R 12各自独立地表示H，卤素原子，C 1 -C 5烷基或苯基; R1和R2各自独立地表示H，羧基，C1-C5烷基，卤素，硝基，C1-C5烷氧基，卤代（C1-C5）烷基，C1-C5烷基羰基，C1-C5烷基羰基氨基，C1-C5烷基磺酰基氨基，苯基磺酰基氨基， C1-C5烷硫基，C1-C5烷基磺酰基或C1-C5烷氧基羰基; R3是H，C1-C5烷基，C1-C5烷氧基或卤代（C1-C5）烷基; R4，R5，R6，R7和R8各自独立地表示H，羧基，C1-C5烷基，硝基，C2-C5烯基，C1-C5烷氧基，C2-C5炔基，卤代（C1-C5）烷基，C1-C5 烷基硫代，C 1 -C 5烷基磺酰基，C 1 -C 5烷基羰基，C 1 -C 5烷氧基羰基，苯基或卤素，其中苯基是未取代的或被至少一个选自羧基，C 1 -C 5烷基，卤素，硝基， C5链烯基，C1-C5烷氧基，卤代（C1-C5）烷基，C1-C5烷基羰基，C1-C5烷硫基，C1-C5烷基磺酰基和C1-C5烷氧基羰基; R9为C1-C5烷基磺酰基或C2-C5链烯基磺酰基; R 10为H，条件是当R3不为H时，R11和R13不能同时表示H。

Patent Agency Ranking